NCT00391092View on ClinicalTrials.gov

A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

PHASE3CompletedINTERVENTIONAL
Enrollment

424

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Breast Cancer
Interventions
DRUG

bevacizumab [Avastin]

15mg/kg iv every 3 weeks

DRUG

Docetaxel

100mg/m2 iv every 3 weeks

DRUG

Herceptin

8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks

Trial Locations (89)

1090

Vienna

1417

Buenos Aires

1650

San Martín

2000

Santa Fe

2076

Wahroonga

2298

Newcastle

2444

Port Macquarie

2480

Lismore

2500

Wollongong

3065

Fitzroy

3220

Geelong

4066

Auchenflower

4400

Salta

4560

Nambour

4840

Vöcklabruck

5004

Córdoba

5020

Salzburg

5500

Mendoza

6000

Perth

7600

Mar del Plata

8036

Graz

11200

Montevideo

11600

Montevideo

14004

Córdoba

14076

Caen

20133

Milan

21079

Dijon

25030

Besançon

27000

Torreón

27100

Pavia

28046

Madrid

33076

Bordeaux

33100

Udine

34298

Montpellier

35100

Izmir

39850

Acapulco

43100

Parma

45100

Guadalajara

50009

Zaragoza

59020

Lille

63011

Clermont-Ferrand

66260

Monterrey

71000

Sarajevo

75000

Tuzla

78000

Banja Luka

84918

Avignon

94805

Villejuif

97500

Mérida

115478

Moscow

197758

Saint Petersburg

249036

Obninsk

390011

Ryazan

400015

Cluj-Napoca

420029

Kazan'

450054

Ufa

700106

Iași

B1902CMK

La Plata

03000

Santa Fe

74605-070

Goiânia

90610-000

Porto Alegre

88034-000

Florianópolis

14784-400

Barretos

01509-010

São Paulo

T2N 4N2

Calgary

V5Z 4E6

Vancouver

B3H 1V7

Halifax

P3E 5J1

Greater Sudbury

L8V 5C2

Hamilton

M4N 3M5

Toronto

H2W 1S6

Montreal

H3A 1A1

Montreal

H3T 1E2

Montreal

G1S 4L8

Québec

S7N 4H4

Saskatoon

128 08

Prague

150 06

Prague

022328

Bucharest

050098

Bucharest

08003

Barcelona

08208

Sabadell, Barcelona

06100

Sıhhiye, Ankara

EX2 5DW

Exeter

SE1 7EH

London

M20 4BX

Manchester

NG5 1PB

Nottingham

PR2 9HT

Preston

LL18 5UJ

Rhyl

ST4 6QG

Stoke-on-Trent

BS23 4TQ

Weston-super-Mare

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00391092 - A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. | Biotech Hunter | Biotech Hunter